Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis

Bhatia, Aakanksha; Ell, Peter J.; Edwards, Jcw

doi:10.1136/ard.2005.036533

Cited by 102 publications

(56 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В 1991 году D'Egidio и Schein [29] предло-жена система классификации, которая учитывает наличие и степень сообщения протоковой систе-мы ПЖ с полостью псевдокисты: 1) острые кисты на фоне неизмененного ПП; 2) кисты, возникающие на фоне ХП с часты-ми протоковокистозными сообщениями, но без стриктур по ходу ПП;…”

Section: операции при кистах поджелудоч-ной железыunclassified

“…В большинстве наблюдений структурное повреждение аорты не ассоциировалось с сохраняющейся активностью заболевания. Показания к регулярной визуализа-ции аорты при ГКА не определены [5,29].…”

Section: клинические проявления гиганто-клеточного артериитаunclassified

“…Ритуксимаб относит-ся к иммуноглобулинам класса G1 (IgG1 каппа). Описан хороший ответ на лечение ритуксимабом у пациента с ГКС-зависимым ГКА [29]. Однако по результатам исследования оценить его эффек-тивность невозможно, т.к.…”

Section: ритуксимабunclassified

“…Впервые о ресвератроле было упомянуто в 1939 году в статье японского ученого Michio Takaoka [27]. С тех пор были обнаружены антиоксидант-ные, ангиопротекторные, противовоспалитель-ные, кардиопротекторные, гепатопротекторные, нейропротекторные, антиканцерогенные, им-муномодулирующие, эстроген-модулирующие, геропротекторные и ряд других важных свойств ресвератрола [24,28,29]. Широта фармаколо-гической активности ресвератрола связана с его влиянием на разные уровни клеточной сигналь-ной трансдукции, главным фигурантом которой является NF-kB [12,30].…”

Section: Introductionunclassified

“…В то же время, на сегодня не опубликовано отчетов о долгосрочных исследо-вания ресвератрола с весомыми конечными точ-ками, такими как выживание при различных ССЗ и другими [29,47]. Однако полученные результа-ты свидетельствуют, что применение ресвератро-ла снижает ХСВ, эндотелиальное повреждение и, соответственно, развитие и прогрессирование АС, а также связанный с ним кардиоваскулярный риск [28,44,47].…”

Section: Introductionunclassified

See 4 more Smart Citations

Untitled

Байтус¹

2017

Vestnik VSMU

View full text Add to dashboard Cite

Section: операции при кистах поджелудоч-ной железыunclassified

Section: клинические проявления гиганто-клеточного артериитаunclassified

Section: ритуксимабunclassified

Section: Introductionunclassified

See 3 more Smart Citations

Untitled

Байтус¹

2017

Vestnik VSMU

View full text Add to dashboard Cite

Disturbed B Cell Homeostasis in Newly Diagnosed Giant Cell Arteritis and Polymyalgia Rheumatica

Geest

Abdulahad

Chalan

et al. 2014

Arthritis & Rheumatology

109

View full text Add to dashboard Cite

Objective. Several lines of evidence indicate that B cells may be involved in the immunopathology of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). This study was undertaken to examine the distribution of defined B cell subsets, including effector B (Beff) cells and regulatory B (Breg) cells, in patients with GCA and patients with PMR before and after corticosteroid treatment.Methods. Circulating B cells were analyzed in 34 newly diagnosed, untreated patients with GCA or PMR, and in 44 followup samples from patients with GCA or PMR who received corticosteroids for 2 weeks or 3 months. For comparison, 40 age-matched healthy controls and 11 rheumatoid arthritis (RA) patients were included. Serum BAFF levels were determined, and temporal arteries were studied by immunohistochemistry.Results Conclusion. We show for the first time that the distribution of B cells is highly disturbed in GCA and PMR and that B cells likely contribute to the enhanced IL-6 response in both diseases.

show abstract

Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Noninflammatory Aortic Aneurysms

Hur

Koster

Jang

et al. 2022

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective To identify hallmark genes and biomolecular processes in aortitis using high‐throughput gene expression profiling, and to provide a range of potentially new drug targets (genes) and therapeutics from a pharmacogenomic network analysis. Methods Bulk RNA sequencing was performed on surgically resected ascending aortic tissues from inflammatory aneurysms (giant cell arteritis [GCA] with or without polymyalgia rheumatica, n = 8; clinically isolated aortitis [CIA], n = 17) and noninflammatory aneurysms (n = 25) undergoing surgical aortic repair. Differentially expressed genes (DEGs) between the 2 patient groups were identified while controlling for clinical covariates. A protein–protein interaction model, drug–gene target information, and the DEGs were used to construct a pharmacogenomic network for identifying promising drug targets and potentially new treatment strategies in aortitis. Results Overall, tissue gene expression patterns were the most associated with disease state than with any other clinical characteristic. We identified 159 and 93 genes that were significantly up‐regulated and down‐regulated, respectively, in inflammatory aortic aneurysms compared to noninflammatory aortic aneurysms. We found that the up‐regulated genes were enriched in immune‐related functions, whereas the down‐regulated genes were enriched in neuronal processes. Notably, gene expression profiles of inflammatory aortic aneurysms from patients with GCA were no different than those from patients with CIA. Finally, our pharmacogenomic network analysis identified genes that could potentially be targeted by immunosuppressive drugs currently approved for other inflammatory diseases. Conclusion We performed the first global transcriptomics analysis in inflammatory aortic aneurysms from surgically resected aortic tissues. We identified signature genes and biomolecular processes, while finding that CIA may be a limited presentation of GCA. Moreover, our computational network analysis revealed potential novel strategies for pharmacologic interventions and suggests future biomarker discovery directions for the precise diagnosis and treatment of aortitis.

show abstract

Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis

Abstract: Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome.

Cited by 102 publications

References 4 publications

Untitled

Untitled

Disturbed B Cell Homeostasis in Newly Diagnosed Giant Cell Arteritis and Polymyalgia Rheumatica

Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Noninflammatory Aortic Aneurysms

Contact Info

Product

Resources

About